{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:12:54Z","timestamp":1793394774273,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002995","name":"University of Dundee School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaip.2025.04.043","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:32:58Z","timestamp":1746531178000},"page":"1943-1951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-2014","authenticated-orcid":false,"given":"Brian J.","family":"Lipworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris RuiWen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.04.043_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2025.04.043_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1017\/S0022215123000853","article-title":"Phenotypic associations of medical polypectomy and revision surgery following endoscopic sinus surgery: a retrospective study of a single-centre experience in Scotland","volume":"137","author":"Misirovs","year":"2023","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.jaip.2025.04.043_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaip.2022.01.040","article-title":"Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma","volume":"10","author":"Chan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.anai.2021.06.007","article-title":"Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma","volume":"127","author":"Chan","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.anai.2023.09.001","article-title":"Type 2 biomarkers and quality of life in chronic rhinosinusitis with nasal polyps","volume":"131","author":"Misirovs","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib6","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.jaip.2021.07.023","article-title":"The choice of biologics in patients with severe chronic rhinosinusitis with nasal polyps","volume":"9","author":"Lipworth","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jaip.2020.03.007","article-title":"Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications","volume":"8","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib8","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.jaip.2023.04.054","article-title":"The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics","volume":"11","author":"Wautlet","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib10","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/all.16519","article-title":"Chinese position paper on biologic therapy for chronic rhinosinusitis with nasal polyps","volume":"80","author":"Xian","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib12","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib13","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"80","author":"Cai","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.043_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.04.043_bib21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2025.04.043_bib23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jaip.2020.10.033","article-title":"Variability in blood eosinophil counts in patients with eosinophilic asthma","volume":"9","author":"Corren","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cea.13310","article-title":"Variability of blood eosinophils in patients in a clinic for severe asthma","volume":"49","author":"Rakowski","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib25","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib26","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.04.043_bib27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib28","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.anai.2025.01.024","article-title":"Real-world effects of tezepelumab on small airway dysfunction in severe refractory asthma","volume":"134","author":"Greig","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/alr.22028","article-title":"Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2025.04.043_bib31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.04.043_bib32","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100934","article-title":"Comparative efficacy of biologics for patients with inadequately controlled asthma: a network meta-analysis","volume":"17","author":"Kim","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.04.043_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jaip.2025.04.043_bib35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.04.043_bib36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/cells11050819","article-title":"Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis","volume":"11","author":"Ando","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaip.2025.04.043_bib37","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/all.16537","article-title":"Head-to-head comparison of biologic efficacy in asthma: what have we learned?","volume":"80","author":"Lipworth","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib38","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1111\/all.16249","article-title":"Effects of dupilumab on quality of life burden in refractory type 2 high unified airway disease","volume":"79","author":"Stewart","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.04.043_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2024.04.015","article-title":"Evaluating an electronic device to monitor the type 2 high unified airway response to dupilumab","volume":"133","author":"Stewart","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982500412X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982500412X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:56:20Z","timestamp":1778853380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982500412X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S221321982500412X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.043","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.04.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}